Changes in HT prescriptions in Australia since 1992

Nathan J. Coombs; John Boyages

Changes in HT prescriptions in Australia since 1992

Nathan J. Coombs, John Boyages^*

^*Corresponding author for this work

Research output: Contribution to journal › Article

7 Citations (Scopus)

Abstract

Hormone therapy (HT) use in Australia and America increased from 1992. However, recent studies have highlighted its risks for breast and endometrial cancer, thromboembolic disorders and cardiovascular disease. One of these studies (the Women’s Health Initiative [WHI] trial) was terminated prematurely because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen. The publicity generated increased public awareness of the risks of HT. This has been further heightened with the publication of the Million Women study. However, the recently published oestrogen only HT (indicated only for women with a hysterectomy because of the risk of endometrial hyperplasia and uterine cancer) arm of the WHI trial suggested that this formulation may reduce the risk of
breast cancer.

Original language	English
Pages (from-to)	697-698
Number of pages	2
Journal	Australian Family Physician
Volume	34
Issue number	8
Publication status	Published - Aug 2005
Externally published	Yes

Keywords

Adult
Australia
Drug Prescriptions
Drug Utilization
Estrogen Replacement Therapy
Female
Humans
Middle Aged
Practice Patterns, Physicians'
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Changes in HT prescriptions in Australia since 1992'. Together they form a unique fingerprint.

Cite this

@article{231d42aa2e2d49d882f1363c347abed8,

title = "Changes in HT prescriptions in Australia since 1992",

abstract = "Hormone therapy (HT) use in Australia and America increased from 1992. However, recent studies have highlighted its risks for breast and endometrial cancer, thromboembolic disorders and cardiovascular disease. One of these studies (the Women’s Health Initiative [WHI] trial) was terminated prematurely because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen. The publicity generated increased public awareness of the risks of HT. This has been further heightened with the publication of the Million Women study. However, the recently published oestrogen only HT (indicated only for women with a hysterectomy because of the risk of endometrial hyperplasia and uterine cancer) arm of the WHI trial suggested that this formulation may reduce the risk of breast cancer.",

keywords = "Adult, Australia, Drug Prescriptions, Drug Utilization, Estrogen Replacement Therapy, Female, Humans, Middle Aged, Practice Patterns, Physicians', Journal Article, Research Support, Non-U.S. Gov't",

author = "Coombs, {Nathan J.} and John Boyages",

year = "2005",

month = "8",

language = "English",

volume = "34",

pages = "697--698",

journal = "Australian family physician.",

issn = "0300-8495",

publisher = "Royal Australian College of General Practitioners",

number = "8",

}

TY - JOUR

T1 - Changes in HT prescriptions in Australia since 1992

AU - Coombs, Nathan J.

AU - Boyages, John

PY - 2005/8

Y1 - 2005/8

N2 - Hormone therapy (HT) use in Australia and America increased from 1992. However, recent studies have highlighted its risks for breast and endometrial cancer, thromboembolic disorders and cardiovascular disease. One of these studies (the Women’s Health Initiative [WHI] trial) was terminated prematurely because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen. The publicity generated increased public awareness of the risks of HT. This has been further heightened with the publication of the Million Women study. However, the recently published oestrogen only HT (indicated only for women with a hysterectomy because of the risk of endometrial hyperplasia and uterine cancer) arm of the WHI trial suggested that this formulation may reduce the risk of breast cancer.

AB - Hormone therapy (HT) use in Australia and America increased from 1992. However, recent studies have highlighted its risks for breast and endometrial cancer, thromboembolic disorders and cardiovascular disease. One of these studies (the Women’s Health Initiative [WHI] trial) was terminated prematurely because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen. The publicity generated increased public awareness of the risks of HT. This has been further heightened with the publication of the Million Women study. However, the recently published oestrogen only HT (indicated only for women with a hysterectomy because of the risk of endometrial hyperplasia and uterine cancer) arm of the WHI trial suggested that this formulation may reduce the risk of breast cancer.

KW - Adult

KW - Australia

KW - Drug Prescriptions

KW - Drug Utilization

KW - Estrogen Replacement Therapy

KW - Female

KW - Humans

KW - Middle Aged

KW - Practice Patterns, Physicians'

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

UR - http://www.scopus.com/inward/record.url?scp=23644454788&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 697

EP - 698

JO - Australian family physician.

JF - Australian family physician.

SN - 0300-8495

IS - 8

ER -